NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is...
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has...
Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable...
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.